<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NANDROLONE DECANOATE- nandrolone decanoate injection </strong><br>Watson Laboratories, Inc.<br></p></div>
<h1>NANDROLONE DECANOATE INJECTION USP<br>
FOR INTRAMUSCULAR USE C-III<br>
Rx only</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">A sterile oleaginous solution containing per mL: Nandrolone Decanoate 100 mg with Benzyl Alcohol 10% as solubilizer/preservative, in Sesame Oil q.s., and Nandrolone Decanoate 200 mg with Benzyl Alcohol 5% as solubilizer/preservative, in Sesame Oil q.s.</p>
<p>Nandrolone decanoate (C<span class="Sub">28</span>H<span class="Sub">44</span>O<span class="Sub">3</span>) occurs as a fine, white to creamy white, crystalline powder. It is odorless, or may have a slight odor.</p>
<p>Nandrolone decanoate is soluble in chloroform, in alcohol, in acetone, and in vegetable oils. It is practically insoluble in water.</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=A586B484-1B46-40B9-9508-FD28002AD383&amp;name=nandrolone-figure-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testis.</p>
<p>Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. These changes revert to normal on discontinuation of treatment.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Nandrolone decanoate is indicated for the management of the <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and has been shown to increase hemoglobin and red cell <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>. Surgically induced anephric patients have been reported to be less responsive.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="AC169BAA-F615-4B69-A51F-184581DDD3B0"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol class="Arabic">
<li><p class="First">Male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate.</p></li>
<li><p class="First">Carcinoma of the breast in females with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>: androgenic anabolic steroids may stimulate osteolytic resorption of bones.</p></li>
<li><p class="First">Pregnancy, because of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">masculinization</span> of the fetus.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrosis</span> or the nephrotic phase of <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ADB27C54-5EDD-4BE4-B5AF-9A7DCCEEB5AE"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<table frame="hsides">
<thead><tr class="First Last"><td class="Lrule" align="left" colspan="2" valign="top"></td></tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">PELIOSIS HEPATIS</span>, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">CYSTS</span>, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">CYSTS</span> ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">LIVER FAILURE</span>. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">LIVER FAILURE</span> OR INTRA-ABDOMINAL <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span> DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS.</span></td>
<td class="Rrule" align="left" rowspan="3" valign="top"></td>
</tr>
<tr><td class="Lrule" align="left" valign="top"><span class="Bold">LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">MALIGNANT TUMORS</span> HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR. HOWEVER, HEPATIC TUMORS ASSOCIATED WITH <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">ANDROGENS</span> OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span> DEVELOPS.</span></td></tr>
<tr><td class="Lrule" align="left" valign="top"><span class="Bold">BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">ATHEROSCLEROSIS</span> ARE SEEN IN PATIENTS TREATED WITH <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">ANDROGENS</span> AND ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEIN AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEIN. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">ATHEROSCLEROSIS</span> AND <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">CORONARY ARTERY DISEASE</span>.</span></td></tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> is associated with therapeutic use of anabolic and androgenic steroids. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> may occur occasionally with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Concomitant administration of adrenal steroids or ACTH may add to the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.</p>
<p>This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="A74770D2-A556-431A-99BB-28109ABC9019"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="AA20CAE8-9E85-43E4-BF6B-F2A1ACC7B2A2"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Women should be observed for signs of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> (deepening of the voice, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="199079" conceptname="Hypertrophy of clitoris">clitorimegaly</span> and menstrual irregularities). Discontinuation of drug therapy at the time of evidence of mild <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilism</span> is necessary to prevent irreversible <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>. Such <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> is usual following anabolic steroid use in high doses.</p>
<p>The insulin or oral hypoglycemic dosage may need adjustment in diabetic patients who receive anabolic steroids.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for patients</h2>
<p class="First">The physician should instruct patients to report any of the following side effects of androgenic anabolic steroids:</p>
<p><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Hoarseness</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, changes in menstrual periods, more hair on the face, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color, or <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="ADD7BDA5-F110-4275-8C9E-63845BB8C7AE"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory tests</h2>
<p class="First">Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of anabolic therapy (see <a href="#ADB27C54-5EDD-4BE4-B5AF-9A7DCCEEB5AE">WARNINGS</a> section).</p>
<p>If children are treated, periodic (every six months) X-ray examinations of bone age should be made during treatment to determine the rate of bone maturation and the effects of anabolic therapy on the epiphyseal centers.</p>
<p>Hemoglobin and hematocrit should be checked periodically for <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span> in patients who are receiving high doses of anabolic steroids.</p>
<p>Serum lipids and high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> should be determined periodically.</p>
<p>Because of the hepatotoxicity associated with the use of 17-alpha-alkylated anabolic steroids, liver function tests should be obtained periodically.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="AE74BD5B-2653-4098-8C53-5919854A149E"></a><a name="section-7.4"></a><p></p>
<h2>Drug interactions</h2>
<p class="First">Anticoagulants. Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time at the desired therapeutic level. Patients receiving oral anticoagulant therapy require close monitoring, especially when anabolic steroids are started or stopped.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.5"></a><p></p>
<h2>Drug/laboratory test interactions</h2>
<p class="First">Anabolic steroid therapy may decrease thyroxine-binding globulin resulting in decreased total T<span class="Sub">4</span> serum levels and increased resin uptake of T<span class="Sub">3</span> and T<span class="Sub">4</span>. Free thyroid hormone levels remain unchanged.</p>
<p>Anabolic steroids may cause an increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Nandrolone decanoate has not been tested in laboratory animals for carcinogenic or mutagenic effects. Liver cell tumors have been reported in patients receiving androgenic anabolic steroid therapy (see <a href="#ADB27C54-5EDD-4BE4-B5AF-9A7DCCEEB5AE">WARNINGS</a> section). Geriatric patients treated with anabolics may be at an increased risk for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category X.</span><br>See <a href="#AC169BAA-F615-4B69-A51F-184581DDD3B0">CONTRAINDICATIONS</a> section.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">It is not known whether anabolic steroids are excreted in human milk. Many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from anabolic steroids, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="AB75652F-0F4C-45D1-AC2E-E8DF45FA119E"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">The safety and efficacy of nandrolone decanoate in children with metastatic breast cancer (rarely found) has not been established. Anabolic agents may accelerate epiphyseal maturation more rapidly than linear growth in children, and the effect may continue for six months after the drug has been stopped. Therefore, therapy should be monitored by X-ray studies at six month intervals in order to avoid the risk of compromising the adult height.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Hepatic:</span></p>
<p>Hepatocellular neoplasms and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> have been reported in association with long-term androgenic anabolic steroid therapy (see <a href="#ADB27C54-5EDD-4BE4-B5AF-9A7DCCEEB5AE">WARNINGS</a> section).</p>
<p><span class="Bold">Genitourinary System:</span></p>
<p>In men. a. Prepubertal: Phallic enlargement and increased frequency of erections. b. Postpubertal: Inhibition of testicular function, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> and <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, chronic <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, <span class="product-label-link" type="condition" conceptid="4150043" conceptname="Epididymitis">epididymitis</span> and <span class="product-label-link" type="condition" conceptid="4227848" conceptname="Bladder irritability">bladder irritability</span>.</p>
<p>In women: Clitoral enlargement, menstrual irregularities.</p>
<p>In both sexes: Increased or decreased libido.</p>
<p><span class="Bold">CNS:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">Habituation</span>, excitation, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">Gastrointestinal:</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Bold">Hematologic:</span></p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> in patients on concomitant anticoagulant therapy (see <a href="#AE74BD5B-2653-4098-8C53-5919854A149E">PRECAUTIONS, Drug Interactions</a>).</p>
<p><span class="Bold">Breast:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>.</p>
<p><span class="Bold">Larynx:</span></p>
<p>Deepening of the voice in women.</p>
<p><span class="Bold">Hair:</span></p>
<p><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span> and male pattern of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">baldness</span> in women.</p>
<p><span class="Bold">Skin:</span></p>
<p><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> (especially in women and prepubertal boys.)</p>
<p><span class="Bold">Skeletal:</span></p>
<p>Premature closure of epiphyses in children (see <a href="#AB75652F-0F4C-45D1-AC2E-E8DF45FA119E">PRECAUTIONS, Pediatric use</a>).</p>
<p><span class="Bold">Fluid and Electrolytes:</span></p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, retention of serum electrolytes (sodium, chloride, potassium, phosphate, calcium).</p>
<p><span class="Bold">Metabolic/Endocrine:</span></p>
<p>Decreased glucose tolerance (see <a href="#AA20CAE8-9E85-43E4-BF6B-F2A1ACC7B2A2">PRECAUTIONS, General</a>), increased serum levels of low-density lipoprotein and decreased levels of high-density lipoprotein (see <a href="#ADD7BDA5-F110-4275-8C9E-63845BB8C7AE">PRECAUTIONS, Laboratory tests</a>), increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK). Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens (see <a href="#A74770D2-A556-431A-99BB-28109ABC9019">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Nandrolone decanoate injection is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no reports of acute overdosage with the anabolics.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Nandrolone decanoate injection is intended for deep intramuscular injection only, into the gluteal muscle preferably.</p>
<p>Dosage should be based on therapeutic response and consideration of the benefit to risk ratio. Duration of therapy will depend on the response of the condition and the appearance of adverse reactions. If possible, therapy should be intermittent.</p>
<p>Nandrolone decanoate should be regarded as adjunctive therapy and adequate quantities of nutrients should be consumed in order to obtain maximal therapeutic effects. For example, when it is used in the treatment of <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span>, adequate iron intake is required for a maximal response.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></span></p>
<p>A dose of 50 to 100 mg per week is recommended for women and 100 to 200 mg per week for men. Drug therapy should be discontinued if no hematologic improvement is seen within the first six months. For children from 2 to 13 years of age, the average dose is 25 to 50 mg every 3 to 4 weeks.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Nandrolone Decanoate Injection USP, 100 mg per mL</span> is available in multiple dose vials of 2 mL, in cartons of 10.</p>
<p><span class="Bold">Nandrolone Decanoate Injection USP, 200 mg per mL</span> is available in single dose vials of 1 mL, in cartons of 25.</p>
<p>Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].<br><span class="Bold">PROTECT FROM LIGHT.</span> Store in carton until contents are used.<br>Literature revised: March 2006</p>
<p>Product Nos.: 0432-02, 0710-01</p>
<p><span class="Bold">Watson Laboratories, Inc.</span></p>
<p>Corona, CA 92880 USA</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NANDROLONE DECANOATE 		
					</strong><br><span class="contentTableReg">nandrolone decanoate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-6717</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Nandrolone Decanoate</strong> (Nandrolone) </td>
<td class="formItem"></td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sesame Oil</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-6717-47</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-6717-02</td>
<td class="formItem">2 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NANDROLONE DECANOATE 		
					</strong><br><span class="contentTableReg">nandrolone decanoate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-2186</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Nandrolone Decanoate</strong> (Nandrolone) </td>
<td class="formItem"></td>
<td class="formItem">200 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sesame Oil</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-2186-53</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-2186-54</td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Watson Laboratories, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>720D97F8-390D-54A5-7DB0-B258E4D77203</div>
<div>Set id: A586B484-1B46-40B9-9508-FD28002AD383</div>
<div>Version: 1</div>
<div>Effective Time: 20070208</div>
</div>
</div> <div class="DistributorName">Watson Laboratories, Inc.</div></p>
</body></html>
